In: NEOPLASMA, vol. 52, no. 3
J. Mardiak - T. Salek - Z. Sycova-Mila - J. Obertova - Z. Hlavata - M. Mego - M. Reckova - I. Koza
Detaily:
Rok, strany: 2005, 243 - 247
O článku:
The aim of the study was to determine the efficacy and toxicity of
gemcitabine, cisplatin and paclitaxel (GCP) combination
as a first salvage treatment of patients with relapsed GCT.
Four courses of paclitaxel 175 mg/m2 and cisplatin 50 mg/m2, both
on day 1, and gemcitabine 1000 mg/m2, on days 1 and
8, every 3 weeks, were given to 12 consecutive patients who had
failed standard 1st line treatment.
Six patients (50%; 95% CI 21-79%) achieved favourable response and
two of them are maintained 38+ and 29+ months.
Median survival time was 16 months (range, 0.77-38+). All, but two
patients had hematological toxicity Gr3-4 with infectious
complication seen only in 6 courses of therapy. GCP is an active
second-line combination regimen for relapsed GCTs
with acceptable toxicity profile. However the results of this
study did not show expected treatment efficacy and we raise the
idea of cisplatin dosage relevance in this combination.
Ako citovať:
ISO 690:
Mardiak, J., Salek, T., Sycova-Mila, Z., Obertova, J., Hlavata, Z., Mego, M., Reckova, M., Koza, I. 2005. Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line
treatment of germ cell tumors (GCT): a phase II study. In NEOPLASMA, vol. 52, no.3, pp. 243-247. 0028-2685.
APA:
Mardiak, J., Salek, T., Sycova-Mila, Z., Obertova, J., Hlavata, Z., Mego, M., Reckova, M., Koza, I. (2005). Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line
treatment of germ cell tumors (GCT): a phase II study. NEOPLASMA, 52(3), 243-247. 0028-2685.